Twitter Facebook LinkedIn YouTube

Voyageur Pharmaceuticals (TSXV:VM) Announced two non-brokered Private Placements

Video Platform Video Management Video Solutions Video Player

The company is looking to raise gross proceeds of up to $600,000 from the placement of up to 12 million units comprised of a combination of both flow-through units and regular units. Regular units are priced at $0.05 per unit and consist of one share and one warrant, with each warrant exercisable at $0.10 for 24 months. Flow-through units are also priced at $0.05 per unit and consist of one share and one-half a warrant, with each full warrant exercisable at $0.12 for 24 months.

Additional Information:

Company: Voyageur Pharmaceuticals
Website: http://www.VoyageurPharmaceuticals.ca
Stock Symbol: TSXV: VM
Date Published: Dec 14, 2020
Transcript: Available

Video Transcript:

I’m Cassandra Bolinski for Investmentpitch Media

Voyageur Pharmaceuticals has announced two non-brokered private placements.

The company is looking to raise gross proceeds of up to $600,000 from the placement of up to 12 million units comprised of a combination of both flow-through units and regular units.

The regular units are priced at $0.05 per unit and consist of one share and one warrant, with each warrant exercisable at $0.10 for 24 months.

The flow-through units are also priced at $0.05 per unit and consist of one share and one-half a warrant, with each full warrant exercisable at $0.12 for 24 months.

All warrants are subject to an acceleration clause.

The units are available in the provinces of Alberta, Saskatchewan, Manitoba, British Columbia, Ontario and Quebec to existing shareholders in addition to the accredited investor and dealer exemptions.

The shares are currently trading at $0.05.

The net proceeds will be used to advance the Frances Creek barium sulfate project, one of the higher grade barium sulfate projects in the world, with approximately $300,000 allocated to update the NI 43-101 report and complete the preliminary economic assessment and pre-feasibility study.

Approximately $150,000 will be used to progress Health Canada and begin FDA drug applications with the remaining $150,000 allocated to planning for production start up, and bulk sample planning and other general corporate purposes.

Voyageur is focused on the development of barite, iodine, and fullerene Active Pharmaceutical Ingredient, or ‘API’ minerals.

The near-term focus is developing barium, iodine radio-contrast products and fullerene-based pharmaceutical products with a goal to initially generate the positive cash flow from operations using third party GMP pharmaceutical manufacturers in Canada and in India.

The company recently signed a non-binding letter of intent with Alberta Veterinarian Laboratories Ltd to manufacture barium radiographic contrast media for Voyageur, with the definitive manufacturing contract expected to be finalized in early 2021.

AVL is a family-owned company, led by Dr. Merle Olson, who is a member of the board of directors of Voyageur.

AVL manufactures both human and veterinarian pharmaceuticals products and operates a Health Canada approved medical testing laboratory.

Ultimately, Voyageur has plans to build all the required infrastructure to become 100% self-sufficient with all manufacturing.

Voyageur owns a 100% interest in three barium sulfate projects in British Columbia including two properties suitable in grade for the industrial barite marketplace, as well as significant interests in a high-grade iodine, lithium & bromine brine project located in Utah, USA.

Voyageur is moving forward with its business plan of becoming the only fully integrated company in the radio-contrast medical field, by controlling all primary input costs under the motto of: "From the Earth to the Bottle"

For more information, please visit www.VoyageurPharmaceuticals.ca, contact Brent Willis, President and CEO, by email at brent@vpharma.ca, or Ron Love, CFO, at 403-818-6086 or by email at ronl@vpharma.ca.

I’m Cassandra Bolinski for Investmentpitch Media